Cargando…

Essential fatty acids for premenstrual syndrome and their effect on prolactin and total cholesterol levels: a randomized, double blind, placebo-controlled study

OBJECTIVE: To evaluate the effectiveness and safety of polyunsaturated fatty acids for the treatment of the premenstrual syndrome (PMS) using a graded symptom scale and to assess the effect of this treatment on basal plasma levels of prolactin and total cholesterol. METHODS: A randomized, double-bli...

Descripción completa

Detalles Bibliográficos
Autores principales: Rocha Filho, Edilberto A, Lima, José C, Pinho Neto, João S, Montarroyos, Ulisses
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033240/
https://www.ncbi.nlm.nih.gov/pubmed/21241460
http://dx.doi.org/10.1186/1742-4755-8-2
_version_ 1782197558621241344
author Rocha Filho, Edilberto A
Lima, José C
Pinho Neto, João S
Montarroyos, Ulisses
author_facet Rocha Filho, Edilberto A
Lima, José C
Pinho Neto, João S
Montarroyos, Ulisses
author_sort Rocha Filho, Edilberto A
collection PubMed
description OBJECTIVE: To evaluate the effectiveness and safety of polyunsaturated fatty acids for the treatment of the premenstrual syndrome (PMS) using a graded symptom scale and to assess the effect of this treatment on basal plasma levels of prolactin and total cholesterol. METHODS: A randomized, double-blind, placebo-controlled study was conducted with 120 women with PMS divided into three groups and treated with 1 or 2 grams of the medication or placebo. Symptoms were recorded over a 6-month period using the Prospective Record of the Impact and Severity of Menstruation (PRISM) calendar. Total cholesterol and prolactin levels were measured. Analysis of variance (ANOVA), Pearson's chi-square test, Wilcoxon's nonparametric signed-rank test for paired samples and the Mann-Whitney nonparametric test for independent samples were used in the statistical analysis. RESULTS: There were no differences in age, marital status, schooling or ethnicity between the groups. In the group treated with 1 gram of the medication, a significant reduction was found when the median PRISM score recorded in the luteal phase at baseline (99) was compared with the median score recorded in the 3(rd )month (58) and in the 6(th )month of evaluation (35). In the 2-gram group, these differences were even more significant (baseline score: 98; 3(rd )month: 48; 6(th )month: 28). In the placebo group, there was a significant reduction at the 3(rd )but not at the 6(th )month (baseline: 96.5; 3(rd )month: 63.5; 6(th )month: 62). The difference between the phases of the menstrual cycle was greater in the 2-gram group compared to the group treated with 1 gram of the medication. There were no statistically significant differences in prolactin or total cholesterol levels between baseline values and those recorded after six months of treatment. CONCLUSION: The difference between the groups using the medication and the placebo group with respect to the improvement in symptomatology appears to indicate the effectiveness of the drug. Improvement in symptoms was higher when the 2-gram dose was used. This medication was not associated with any changes in prolactin or total cholesterol levels in these women.
format Text
id pubmed-3033240
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30332402011-02-04 Essential fatty acids for premenstrual syndrome and their effect on prolactin and total cholesterol levels: a randomized, double blind, placebo-controlled study Rocha Filho, Edilberto A Lima, José C Pinho Neto, João S Montarroyos, Ulisses Reprod Health Research OBJECTIVE: To evaluate the effectiveness and safety of polyunsaturated fatty acids for the treatment of the premenstrual syndrome (PMS) using a graded symptom scale and to assess the effect of this treatment on basal plasma levels of prolactin and total cholesterol. METHODS: A randomized, double-blind, placebo-controlled study was conducted with 120 women with PMS divided into three groups and treated with 1 or 2 grams of the medication or placebo. Symptoms were recorded over a 6-month period using the Prospective Record of the Impact and Severity of Menstruation (PRISM) calendar. Total cholesterol and prolactin levels were measured. Analysis of variance (ANOVA), Pearson's chi-square test, Wilcoxon's nonparametric signed-rank test for paired samples and the Mann-Whitney nonparametric test for independent samples were used in the statistical analysis. RESULTS: There were no differences in age, marital status, schooling or ethnicity between the groups. In the group treated with 1 gram of the medication, a significant reduction was found when the median PRISM score recorded in the luteal phase at baseline (99) was compared with the median score recorded in the 3(rd )month (58) and in the 6(th )month of evaluation (35). In the 2-gram group, these differences were even more significant (baseline score: 98; 3(rd )month: 48; 6(th )month: 28). In the placebo group, there was a significant reduction at the 3(rd )but not at the 6(th )month (baseline: 96.5; 3(rd )month: 63.5; 6(th )month: 62). The difference between the phases of the menstrual cycle was greater in the 2-gram group compared to the group treated with 1 gram of the medication. There were no statistically significant differences in prolactin or total cholesterol levels between baseline values and those recorded after six months of treatment. CONCLUSION: The difference between the groups using the medication and the placebo group with respect to the improvement in symptomatology appears to indicate the effectiveness of the drug. Improvement in symptoms was higher when the 2-gram dose was used. This medication was not associated with any changes in prolactin or total cholesterol levels in these women. BioMed Central 2011-01-17 /pmc/articles/PMC3033240/ /pubmed/21241460 http://dx.doi.org/10.1186/1742-4755-8-2 Text en Copyright ©2011 Rocha Filho et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Rocha Filho, Edilberto A
Lima, José C
Pinho Neto, João S
Montarroyos, Ulisses
Essential fatty acids for premenstrual syndrome and their effect on prolactin and total cholesterol levels: a randomized, double blind, placebo-controlled study
title Essential fatty acids for premenstrual syndrome and their effect on prolactin and total cholesterol levels: a randomized, double blind, placebo-controlled study
title_full Essential fatty acids for premenstrual syndrome and their effect on prolactin and total cholesterol levels: a randomized, double blind, placebo-controlled study
title_fullStr Essential fatty acids for premenstrual syndrome and their effect on prolactin and total cholesterol levels: a randomized, double blind, placebo-controlled study
title_full_unstemmed Essential fatty acids for premenstrual syndrome and their effect on prolactin and total cholesterol levels: a randomized, double blind, placebo-controlled study
title_short Essential fatty acids for premenstrual syndrome and their effect on prolactin and total cholesterol levels: a randomized, double blind, placebo-controlled study
title_sort essential fatty acids for premenstrual syndrome and their effect on prolactin and total cholesterol levels: a randomized, double blind, placebo-controlled study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033240/
https://www.ncbi.nlm.nih.gov/pubmed/21241460
http://dx.doi.org/10.1186/1742-4755-8-2
work_keys_str_mv AT rochafilhoedilbertoa essentialfattyacidsforpremenstrualsyndromeandtheireffectonprolactinandtotalcholesterollevelsarandomizeddoubleblindplacebocontrolledstudy
AT limajosec essentialfattyacidsforpremenstrualsyndromeandtheireffectonprolactinandtotalcholesterollevelsarandomizeddoubleblindplacebocontrolledstudy
AT pinhonetojoaos essentialfattyacidsforpremenstrualsyndromeandtheireffectonprolactinandtotalcholesterollevelsarandomizeddoubleblindplacebocontrolledstudy
AT montarroyosulisses essentialfattyacidsforpremenstrualsyndromeandtheireffectonprolactinandtotalcholesterollevelsarandomizeddoubleblindplacebocontrolledstudy